FRI0349 A Survival Analysis of Patients with Primary Sjögren's Syndrome. (15th July 2016)

• Record Type: Journal Article
• Authors: Yazisiz, V.; Göçer, M.; Oygen, S.; Avci, A.B.; Gökalp, E.; Terzioğlu, E.
• Is Part Of: Annals of the rheumatic diseases. Volume 75(2016)Supplement 2
• Page Start: 561
• Page End: 561
• Publication Date: 2016-07-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2016-eular.3742
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease with unknown aetiology and involves mainly salivary and lacrimal glands. It is an autoimmune disease with a broad range of systemic manifestations. Mortality rate might reduce in pSS patients with treated new medications. There is no information on survival of pSS patients in our country. Objectives: This study was conducted to determine clinical features and survival in pSS patients Methods: All pSS patients who diagnosed betwen 2004–2014 years were included in this study. The clinical and laboratory features and mortality rates were reevaluated Results: There were 718 patients with suspected pSS at 10 years. 372 patients were classified as pSS according to 2012 American Collage of Rheumatology Classification Criteria for Sjögren's Syndrome. Women/men ratio was 11/1. The mean age at the time of diagnosis was 50.3±11.81 years. 14 patients (3.8%) were diagnosed different malignancy and 18 patients died (4.8%). The rate of 10-year survival was 95.6% (%96.6 for women, %86.6 for men, p:0.004). 10-year survival rate was % 98.7 in patients without pulmonary involvement, but 79.2% in patients with pulmonary involvement. Multivariate Cox analysis showed that pulmonary involvement (OR:12.8, %95 CI: 4.52–44.8, p<0.001) and male gender (OR:1.7%95, CI: 1.17–4.53, p=0.004) were independent mortality risk factors Conclusions: Our data revealed that cumulative survival was 95.6% at 10 years in pSS patients. Pulmonary involvement represented the main cause of death. pSS patients with pulmoner involvement have greater risk of death. Disclosure of Interest: None declared